In Takeda/Shire [1], the European Commission has conditionally cleared a concentration between two drug manufacturers by accepting a divestment remedy in the context of the Phase I Investigation. The planned merger operation Takeda and Shire are two major global pharmaceutical companies headquartered in Japan and Jersey, respectively. Their product portfolios are largely complementary with Shire focused on rare genetic diseases and immunology and Takeda on vaccines, oncology and gastroenterology. By the notified merger, Takeda intended to acquire the sole control over Shire. The decision of the Commission Though the proposed merger might potentially affect several pharmaceutical markets, the Commission had concerns that the transaction would harm competition only in the market for
Share on
|
|
The EU Commission conditionally approves an acquisition in the pharmaceutical sector (Takeda / Shire)
Access to this article is restricted to subscribers
Already Subscribed? Sign-in
Access to this article is restricted to subscribers.
Read one article for free
Sign-up to read this article for free and discover our services.
